Related Experiment Videos
Safety of gadolinium contrast agent in hemodialysis patients
S Okada1, K Katagiri, T Kumazaki
1Department of Radiology, Nippon Medical School Chiba-Hokuso Hospital, Japan.
Insights
Gadolinium (Gd) contrast agents are safe for hemodialysis patients. Prompt hemodialysis after contrast-enhanced MRI effectively removes Gd, preventing adverse effects and blood changes.
Area of Science:
- Nephrology
- Radiology
- Pharmacology
Background:
- Gadolinium-based contrast agents (GBCAs) are widely used in magnetic resonance imaging (MRI).
- Concerns exist regarding the retention of gadolinium in patients with impaired renal function, particularly those undergoing hemodialysis.
Purpose of the Study:
- To evaluate the safety and efficacy of gadolinium contrast agent administration in patients undergoing maintenance hemodialysis.
- To assess the rate of gadolinium excretion following hemodialysis sessions post-contrast enhanced MRI.
Main Methods:
- Seventy hemodialysis patients received gadolinium contrast agents for MRI examinations.
- Patients underwent hemodialysis sessions at varying intervals post-imaging.
- Serum gadolinium concentrations were measured before and after serial hemodialysis sessions in a subset of patients.
- Systematic monitoring for cardiovascular, cutaneous, respiratory, neurological, and digestive side effects was conducted.
Main Results:
- No adverse side effects or significant changes in blood parameters were observed in any of the study participants.
- Average gadolinium excretion rates increased progressively with each hemodialysis session, reaching 99.5% by the fourth session.
- Rapid and efficient clearance of gadolinium was demonstrated through timely hemodialysis.
Conclusions:
- Gadolinium contrast agents can be safely administered to hemodialysis patients.
- Prompt initiation of hemodialysis following contrast-enhanced MRI facilitates effective gadolinium elimination.
- This study supports the judicious use of GBCAs in this patient population when appropriate precautions are taken.
Purpose:
We evaluated the safety of a gadolinium (Gd) contrast agent in hemodialysis patients.
Material And Methods:
Seventy hemodialysis patients underwent contrast-enhanced MR examination. After the examination, the patients were hemodialyzed on a usual schedule, i.e., 3 times per week at 4 h each session. The hemodialysis was performed on the same day in 16 patients, the next day in 34, 2 days later in 14 and 3 days later in 6 patients. Serum Gd concentrations before and after the first to fourth hemodialysis sessions were analyzed in 11 patients. Cardiovascular, cutaneous, respiratory, psycho-neurological and digestive side effects were evaluated in all patients. Changes in liver and kidney functions, blood counts, and electrolytes were also checked.
Results And Conclusion:
Neither side effects nor blood changes were noted in any of the patients. Average excretory rates were 78.2%, 95.6%, 98.7% and 99.5% in the first to fourth hemodialysis sessions, respectively. These results suggest that Gd contrast agents can be used in hemodialysis patients if hemodialysis is carried out promptly after the examination.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Imaging Studies III: Computed Tomography
Imaging Studies VII: Vascular Imaging
Hemodialysis III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...